# OnCo record histology-directs-first-line-meso (pairing). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pairings/histology-directs-first-line-meso/>
  a schema:MedicalTherapy ;
  onco:kind "pairing" ;
  schema:identifier "histology-directs-first-line-meso" ;
  schema:name "Histology → first-line choice in mesothelioma"@en ;
  schema:description "Read the tumour type under the microscope first: non-epithelioid tumours should get immunotherapy up front; epithelioid tumours can reasonably get either immunotherapy or chemo-immunotherapy."@en ;
  schema:url <https://onco.cc/pairings/histology-directs-first-line-meso/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02899299>, <https://clinicaltrials.gov/study/NCT02784171> ;
  onco:cancers <https://onco.cc/cancers/mesothelioma/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/pemetrexed/> ;
  onco:terms <https://onco.cc/terms/epithelioid-vs-sarcomatoid/> ;
  onco:trials <https://onco.cc/trials/checkmate-743/>, <https://onco.cc/trials/keynote-483/> ;
  onco:pairs <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/checkpoint-inhibitor/> .